Lithuanian Firm Develops AI for Multi-Omics Integration
Lithuanian bioinformatics company Vugene is developing a platform that uses automation and AI to integrate multi-omics data for clinical trials. The technology combines datasets from genomics, proteomics, and metabolomics to provide a more complete biological picture for researchers. The company's work highlights a growing trend in computational biology toward synthesizing multiple data types to uncover deeper mechanistic insights.
- The company, Vugene, was founded in 2021 by bioinformatics scientist Juozas Gordevičius and secured €1 million in its first venture funding round in May 2024. It operates on a "Service-as-a-Software" model, where clients provide biological data and Vugene delivers the scientific insights. - A primary challenge in multi-omics is integrating heterogeneous data; information from genomics, proteomics, and other layers have different formats and levels of quality, complicating analysis. Another significant hurdle is the problem of "high dimensionality," where the number of biological variables is much larger than the number of samples or patients, which can challenge machine learning algorithms. - Professionals in computational biology and bioinformatics typically spend their days working on computers, writing and debugging code in languages like Python and R, and using high-performance computing clusters to analyze large datasets. Their work often involves collaborating with "wet lab" scientists who generate the initial biological data.
